Anpario is recommending a final dividend of 8.90 pence per share (2024: 8.00 pence), payable on 24 July 2026 to shareholders on the register on 10 July 2026 (ex-dividend date of 9 July 2026). In addition to the interim dividend already paid, this represents an increase in the total dividend for the year of 11% to 12.50 pence per share (2024: 11.25 pence).
An interim dividend of 3.60p per share was paid on 28 November 2025. Anpario is proposing a final dividend of 8.90p per share, subject to shareholder approval at the Annual General Meeting, payable on 24 July 2026 to shareholders on the register on 10 July 2026. Taken together, the interim dividend paid and the proposed final dividend represent a total dividend for the year of 12.50p per share (2024: 11.25p).
Therefore, Anpario will recommend the final dividend of 8.90 pence per share at the forthcoming Annual General Meeting ("AGM"), resulting in a total of 12.50 pence per share for the year (2024: 11.25 pence), an increase of 11%. This dividend, payable on 24 July 2026 to shareholders on the register on 10 July 2026 (ex-dividend date of 9 July 2026), reflects Anpario’s ability to generate strong cash flows.
Other Financial Highlights:
- Revenue increased by 24% to £47.2m (2024: £38.2m), supported by the first full year contribution from the acquisition of Bio-Vet, which added £6.7m this year and £2.2m of revenue in 2024 in the three months post-acquisition. Excluding Bio-Vet, revenue increased by 12% on a like-for-like basis to £40.5m (2024: £36.0m), reflecting strong demand across Anpario’s territories.
- Profitability strengthened, with gross profit increasing by 34% to £24.0m (2024: £17.9m) and gross margin improving to 50.9% (2024: 46.9%). Adjusted EBITDA increased by 38% to £9.6m (2024: £7.0m) and profit before tax rose by 54% to £8.0m (2024: £5.2m), demonstrating the operational leverage in Anpario’s business model. The balance sheet remained strong, with cash and cash equivalents of £12.4m at the year-end (2024: £10.5m), after dividend payments of £2.1m and final payments related to the Bio-Vet acquisition of £1.0m, reflecting continued strong cash generation.
